GlassScriptPhysician profile
Kenneth P Toler
NPI 1841295573
$2,557.21
in general payments reported to CMS, 2019-2025
14 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $242 · 2021: $339 · 2022: $448 · 2023: $288 · 2024: $363 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.46 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,527.80 | 2019-2025 | Clareon, Rocklatan, Total30 |
| Abbvie INC. | $368.88 | 2022-2025 | Durysta |
| Rxsight INC | $210.27 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Biotissue Holdings INC. | $86.70 | 2022-2024 | |
| Horizon Therapeutics Plc | $79.84 | 2022-2023 | Tepezza |
| Omeros Corporation | $71.37 | 2020 | |
| Mallinckrodt Hospital Products INC. | $43.02 | 2025 | Acthar |
| Allergan, INC. | $41.42 | 2021 | |
| Sun Pharmaceutical Industries INC. | $36.22 | 2019-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $26.40 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $19.96 | 2021 | |
| Amgen INC. | $18.33 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $15.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Toler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.